Covaxin's emergency nod push in US fails

By Online Desk
According to news agencies, Covaxin shows 77.8 per cent efficacy in phase 3 trial data in review by Subject Expert Committee (SEC).

The Subject Expert Committee was to meet today to review the Phase III data of Covaxin.

Bharat Biotech’s Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.

#Breaking: @CDSCO_INDIA_INF approves phase 3 trial data of @BharatBiotech ‘s #Covaxin showing 77.8 % efficacy against #COVID19 infection. @NewIndianXpress #CovidVaccine
— Sumi Dutta (@SumiSukanya) June 22, 2021

The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).


(This is a developing story. More details awaited.)